Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells

Journal of Immunology

Volumn 193, Issue 11, 2014, Pages 5723-5732

  Pardee, Angela D ^a   Shi, Jian ^a   Butterfield, Lisa H ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; B7 ANTIGEN; CD14 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CXCL1 CHEMOKINE; HLA ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; AUTACOID; CHAPERONE; CYTOKINE; LEUKOCYTE ANTIGEN;

ARTICLE; BONE MARROW CELL; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; GENE CONTROL; HUMAN; HUMAN CELL; IMMUNOREGULATION; LIVER CELL CARCINOMA; MOLECULAR WEIGHT; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WESTERN BLOTTING; FETUS BLOOD; HEPG2 CELL LINE; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM;

ALPHA-FETOPROTEINS; ANTIGENS, CD; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; DENDRITIC CELLS; FETAL BLOOD; HEP G2 CELLS; HUMANS; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; MOLECULAR CHAPERONES; T-LYMPHOCYTES;

EID: 84912569466     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400725     Document Type: Article

References (43)

1. Tomasi, T. B., Jr. 1977. Structure and function of alpha-fetoprotein. Annu. Rev. Med. 28: 453-465.
2. Mizejewski, G. J. 2002. Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev. Anticancer Ther. 2: 709-735.
3. Johnson, P. J., T. C. Poon, N. M. Hjelm, C. S. Ho, S. K. Ho, C. Welby, D. Stevenson, T. Patel, R. Parekh, and R. R. Townsend. 1999. Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour. Br. J. Cancer 81: 1188-1195.
4. Mizejewski, G. J. 2001. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp. Biol. Med. (Maywood) 226: 377-408.
5. Li, M., H. Li, C. Li, S. Zhou, L. Guo, H. Liu, W. Jiang, X. Liu, P. Li, M. A. McNutt, and G. Li. 2009. Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells. Int. J. Cancer 124: 2845-2854.
6. Li, M., H. Li, C. Li, S. Wang, W. Jiang, Z. Liu, S. Zhou, X. Liu, M. A. McNutt, and G. Li. 2011. Alpha-fetoprotein: a new member of intracellular signal molecules in regulation of the PI3K/AKT signaling in human hepatoma cell lines. Int. J. Cancer 128: 524-532.
7. Cohen, B. L., A. Orn, K. O. Gronvik, M. Gidlund, H. Wigzell, and R. A. Murgita. 1986. Suppression by alpha-fetoprotein of murine natural killer cell activity stimulated in vitro and in vivo by interferon and interleukin 2. Scand. J. Immunol. 23: 211-223.
8. Yachnin, S. 1976. Demonstration of the inhibitory effect of human alphafetoprotein on in vitro transformation of human lymphocytes. Proc. Natl. Acad. Sci. USA 73: 2857-2861.
9. Um, S. H., C. Mulhall, A. Alisa, A. R. Ives, J. Karani, R. Williams, A. Bertoletti, and S. Behboudi. 2004. Alpha-fetoprotein impairs APC function and induces their apoptosis. J. Immunol. 173: 1772-1778.
10. Yamamoto, M., T. Tatsumi, T. Miyagi, H. Tsunematsu, H. Aketa, A. Hosui, T. Kanto, N. Hiramatsu, N. Hayashi, and T. Takehara. 2011. a-Fetoprotein impairs activation of natural killer cells by inhibiting the function of dendritic cells. Clin. Exp. Immunol. 165: 211-219.
11. Ritter, M., M. Y. Ali, C. F. Grimm, R. Weth, L. Mohr, W. O. Bocher, K. Endrulat, H. Wedemeyer, H. E. Blum, and M. Geissler. 2004. Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. J. Hepatol. 41: 999-1007.
12. Setiyono, A., A. D. Budiyati, S. Purwantomo, M. R. Anggelia, I. Fanany, G. A. Wibowo, I. Bachtiar, A. Utama, and S. Tai. 2011. Immunoregulatory effects of AFP domains on monocyte-derived dendritic cell function. BMC Immunol. 12: 4.
13. Behboudi, S., and S. P. Pereira. 2010. Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma. World J. Hepatol. 2: 256-260.
14. Butterfield, L. H., W. S. Meng, A. Koh, C. M. Vollmer, A. Ribas, V. B. Dissette, K. Faull, J. A. Glaspy, W. H. McBride, and J. S. Economou. 2001. T cell responses to HLA-A∗0201-restricted peptides derived from human alpha fetoprotein. J. Immunol. 166: 5300-5308.
15. Butterfield, L. H., A. Ribas, W. S. Meng, V. B. Dissette, S. Amarnani, H. T. Vu, E. Seja, K. Todd, J. A. Glaspy, W. H. McBride, and J. S. Economou. 2003. T-cell responses to HLA-A∗0201 immunodominant peptides derived from alphafetoprotein in patients with hepatocellular cancer. Clin. Cancer Res. 9: 5902-5908.
16. Butterfield, L. H., A. Ribas, V. B. Dissette, Y. Lee, J. Q. Yang, P. De la Rocha, S. D. Duran, J. Hernandez, E. Seja, D. M. Potter, et al. 2006. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin. Cancer Res. 12: 2817-2825.
17. Potter, D. M., L. H. Butterfield, S. J. Divito, C. A. Sander, and J. M. Kirkwood. 2012. Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients. J. Immunol. Methods 376: 108-112.
18. Ormandy, L. A., A. Farber, T. Cantz, S. Petrykowska, H. Wedemeyer, M. Horning, F. Lehner, M. P. Manns, F. Korangy, and T. F. Greten. 2006. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J. Gastroenterol. 12: 3275-3282.
19. Wertheimer, A. M., A. Bakke, and H. R. Rosen. 2004. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology 40: 335-345.
20. Lechner, M. G., C. Megiel, S. M. Russell, B. Bingham, N. Arger, T. Woo, and A. L. Epstein. 2011. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J. Transl. Med. 9: 90.
21. Loetscher, P., M. Seitz, I. Clark-Lewis, M. Baggiolini, and B. Moser. 1996. Activation of NK cells by CC chemokines. Chemotaxis, Ca2+ mobilization, and enzyme release. J. Immunol. 156: 322-327.
22. Vujanovic, L., W. Ballard, S. H. Thorne, N. L. Vujanovic, and L. H. Butterfield. 2012. Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10. OncoImmunology 1: 448-457.
23. Li, Q., and I. M. Verma. 2002. NF-kappaB regulation in the immune system. [Published erratum appears in 2002 Nat. Rev. Immunol. 2: 975.] Nat. Rev. Immunol. 2: 725-734.
24. Uversky, V. N., M. D. Kirkitadze, N. V. Narizhneva, S. A. Potekhin, and Tomashevski AYu. 1995. Structural properties of alpha-fetoprotein from human cord serum: the protein molecule at low pH possesses all the properties of the molten globule. FEBS Lett. 364: 165-167.
25. Lester, E. P., J. B. Miller, and S. Yachnin. 1976. Human alpha-fetoprotein as a modulator of human lymphocyte transformation: correlation of biological potency with electrophoretic variants. Proc. Natl. Acad. Sci. USA 73: 4645-4648.
26. Miyoshi, E., K. Moriwaki, and T. Nakagawa. 2008. Biological function of fucosylation in cancer biology. J. Biochem. 143: 725-729.
27. Kakumu, S., S. Ito, T. Ishikawa, Y. Mita, T. Tagaya, Y. Fukuzawa, and K. Yoshioka. 2000. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J. Gastroenterol. Hepatol. 15: 431-436.
28. Hargadon, K. M. 2013. Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front. Immunol. 4: 192.
29. Salazar-Mather, T. P., T. A. Hamilton, and C. A. Biron. 2000. A chemokine-to-cytokine-to-chemokine cascade critical in antiviral defense. J. Clin. Invest. 105: 985-993.
30. Cai, L., Z. Zhang, L. Zhou, H.Wang, J. Fu, S. Zhang, M. Shi, H. Zhang, Y. Yang, H. Wu, et al. 2008. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin. Immunol. 129: 428-437.
31. Chew, V., J. Chen, D. Lee, E. Loh, J. Lee, K. H. Lim, A. Weber, K. Slankamenac, R. T. Poon, H. Yang, et al. 2012. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 61: 427-438.
32. Guy, C. S., K. M. Vignali, J. Temirov, M. L. Bettini, A. E. Overacre, M. Smeltzer, H. Zhang, J. B. Huppa, Y. H. Tsai, C. Lobry, et al. 2013. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat. Immunol. 14: 262-270.
33. Smith, C. J., A. Ajdukiewicz, and P. C. Kelleher. 1983. Concanavalin-A-affinity molecular heterogeneity of human hepatoma AFP and cord-serum AFP. Ann. N. Y. Acad. Sci. 417: 69-74.
34. Semeniuk, D. J., R. Boismenu, J. Tam, W. Weissenhofer, and R. A. Murgita. 1995. Evidence that immunosuppression is an intrinsic property of the alphafetoprotein molecule. Adv. Exp. Med. Biol. 383: 255-269.
35. Parmelee, D. C., M. A. Evenson, and H. F. Deutsch. 1978. The presence of fatty acids in human alpha-fetoprotein. J. Biol. Chem. 253: 2114-2119.
36. Aoyagi, Y., T. Ikenaka, and F. Ichida. 1979. alpha-Fetoprotein as a carrier protein in plasma and its bilirubin-binding ability. Cancer Res. 39: 3571-3574.
37. Zeyda, M., M. D. Säemann, K. M. Stuhlmeier, D. G. Mascher, P. N. Nowotny, G. J. Zlabinger, W. Waldhä usl, and T. M. Stulnig. 2005. Polyunsaturated fatty acids block dendritic cell activation and function independently of NF-kappaB activation. J. Biol. Chem. 280: 14293-14301.
38. Widner, B., B. Wirleitner, G. Baier-Bitterlich, G. Weiss, and D. Fuchs. 2000. Cellular immune activation, neopterin production, tryptophan degradation and the development of immunodeficiency. Arch. Immunol. Ther. Exp. (Warsz.) 48: 251-258.
39. Liu, Y., P. Li, J. Lu, W. Xiong, J. Oger, W. Tetzlaff, and M. Cynader. 2008. Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis. J. Immunol. 181: 1887-1897.
40. Nishihira, J., Y. Koyama, M. Sakai, and S. Nishi. 1993. The fatty acid binding site of human alpha-fetoprotein. Biochem. Biophys. Res. Commun. 196: 1049-1057.
41. Parker, M. H., E. Birck-Wilson, G. Allard, N. Masiello, M. Day, K. P. Murphy, V. Paragas, S. Silver, and M. D. Moody. 2004. Purification and characterization of a recombinant version of human alpha-fetoprotein expressed in the milk of transgenic goats. Protein Expr. Purif. 38: 177-183.
42. Pardee, A. D., and L. H. Butterfield. 2012. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. OncoImmunology 1: 48-55.
43. Lee, W. C., H. C. Wang, C. F. Hung, P. F. Huang, C. R. Lia, and M. F. Chen. 2005. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J. Immunother. 28: 496-504.